[
  {
    "ts": null,
    "headline": "Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey",
    "summary": "Companies have slowly been increasing coverage of GLP-1s for weight loss. Still, fewer than 50% do so.",
    "url": "https://finnhub.io/api/news?id=d4254328492e854aa93f2b4a16af1d2402a1ecc8b031e22a23e4dbd465e6ec38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736372698,
      "headline": "Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey",
      "id": 132331977,
      "image": "https://s.yimg.com/ny/api/res/1.2/DjGoNGoGT5.XsXrhoJ8jIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://s.yimg.com/os/creatr-uploaded-images/2025-01/28b7a610-ce04-11ef-b7db-5112d2e9e0ce",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies have slowly been increasing coverage of GLP-1s for weight loss. Still, fewer than 50% do so.",
      "url": "https://finnhub.io/api/news?id=d4254328492e854aa93f2b4a16af1d2402a1ecc8b031e22a23e4dbd465e6ec38"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition",
    "summary": "Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products",
    "url": "https://finnhub.io/api/news?id=0cd06e3e437361c100c87f0f45ea31ab4208267f0b27a266785ca1e1796f49ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736363771,
      "headline": "Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition",
      "id": 132331978,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/de028088c2fb810b95745f672ea59104",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products",
      "url": "https://finnhub.io/api/news?id=0cd06e3e437361c100c87f0f45ea31ab4208267f0b27a266785ca1e1796f49ab"
    }
  },
  {
    "ts": null,
    "headline": "Trump suggests Denmark tariff. How it could hit Novo Nordisk.",
    "summary": "President-elect Donald Trump threatened higher tariffs against longtime ally Denmark over its ownership of Greenland as a Danish territory; Trump even floated the idea of the US purchasing Greenland. Denmark-based pharmaceutical company Novo Nordisk (NVO) is a major company that could be heavily impacted if Trump were to impose such tariffs. Yahoo Finance senior health reporter Anjalee Khemlani explains Novo Nordisk's presence in the US, especially as a GLP-1 weight-loss drug manufacturer, and what US companies like Eli Lilly (LLY) could have to gain if tariffs were levied against Denmark producers. Trump has proposed new tariff policy proposals that he could enact using the International Economic Emergency Powers Act (IEEPA). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=e033ff82cae4ec024cf1c3f023f0638e461a957bcce8abccdf02d03cc866527e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736348796,
      "headline": "Trump suggests Denmark tariff. How it could hit Novo Nordisk.",
      "id": 132316865,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President-elect Donald Trump threatened higher tariffs against longtime ally Denmark over its ownership of Greenland as a Danish territory; Trump even floated the idea of the US purchasing Greenland. Denmark-based pharmaceutical company Novo Nordisk (NVO) is a major company that could be heavily impacted if Trump were to impose such tariffs. Yahoo Finance senior health reporter Anjalee Khemlani explains Novo Nordisk's presence in the US, especially as a GLP-1 weight-loss drug manufacturer, and what US companies like Eli Lilly (LLY) could have to gain if tariffs were levied against Denmark producers. Trump has proposed new tariff policy proposals that he could enact using the International Economic Emergency Powers Act (IEEPA). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=e033ff82cae4ec024cf1c3f023f0638e461a957bcce8abccdf02d03cc866527e"
    }
  },
  {
    "ts": null,
    "headline": "This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly",
    "summary": "Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications.  One study suggests that it may even help reduce the risk of developing Alzheimer's.  There are many illnesses and conditions which are associated with being obese, which is why it's paramount for many patients to maintain a healthy weight.",
    "url": "https://finnhub.io/api/news?id=d5da7b765c713c8ac87ebb1efaeac6b1fde8bdf0a346704a1792d4c36710fbb6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736347500,
      "headline": "This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly",
      "id": 132316366,
      "image": "https://g.foolcdn.com/editorial/images/802830/doctor-giving-a-patient-medication.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due to their successful diabetes and weight loss medications.  One study suggests that it may even help reduce the risk of developing Alzheimer's.  There are many illnesses and conditions which are associated with being obese, which is why it's paramount for many patients to maintain a healthy weight.",
      "url": "https://finnhub.io/api/news?id=d5da7b765c713c8ac87ebb1efaeac6b1fde8bdf0a346704a1792d4c36710fbb6"
    }
  },
  {
    "ts": null,
    "headline": "5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher",
    "summary": "Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of America addresses the company’s earnings and more.",
    "url": "https://finnhub.io/api/news?id=dc9f97067c224221aab0ea977c0112e8b570af743d83bc1d33c576dbb271ddad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736347500,
      "headline": "5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher",
      "id": 132316869,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of America addresses the company’s earnings and more.",
      "url": "https://finnhub.io/api/news?id=dc9f97067c224221aab0ea977c0112e8b570af743d83bc1d33c576dbb271ddad"
    }
  },
  {
    "ts": null,
    "headline": "3 US Stocks Estimated To Be Undervalued By Up To 47.7%",
    "summary": "As the U.S. stock market experiences fluctuations driven by rising Treasury yields and mixed economic data, investors are closely monitoring opportunities that may arise from these shifts. In this environment, identifying undervalued stocks can be crucial for those looking to capitalize on potential market inefficiencies, especially as interest rate expectations continue to evolve.",
    "url": "https://finnhub.io/api/news?id=9729c13ce740af4fa51e86bcd7fbcab3a779bf0965ed072911ff2a492c51f9a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736330536,
      "headline": "3 US Stocks Estimated To Be Undervalued By Up To 47.7%",
      "id": 132315796,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/a3ab99500bb842820119e0d737ca7bfe",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the U.S. stock market experiences fluctuations driven by rising Treasury yields and mixed economic data, investors are closely monitoring opportunities that may arise from these shifts. In this environment, identifying undervalued stocks can be crucial for those looking to capitalize on potential market inefficiencies, especially as interest rate expectations continue to evolve.",
      "url": "https://finnhub.io/api/news?id=9729c13ce740af4fa51e86bcd7fbcab3a779bf0965ed072911ff2a492c51f9a4"
    }
  },
  {
    "ts": null,
    "headline": "CURE: Analyst Estimates Point To Significant Gains In 2025",
    "summary": "The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=d511117d3542b3c924b27ade3e17e3d5a504a7d2af3c6fa8d68efe57e54c1850",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736327815,
      "headline": "CURE: Analyst Estimates Point To Significant Gains In 2025",
      "id": 132315626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Direxion Daily Healthcare Bull 3X Shares ETF seeks to deliver 300% (3x) of the return of an index focused on large-cap US healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=d511117d3542b3c924b27ade3e17e3d5a504a7d2af3c6fa8d68efe57e54c1850"
    }
  },
  {
    "ts": null,
    "headline": "3 trial readouts that could shake up the obesity market this year",
    "summary": "A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.",
    "url": "https://finnhub.io/api/news?id=f3086c06d83cacc3193673dc327878c7d13d61343e637371455421df91c72968",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736318764,
      "headline": "3 trial readouts that could shake up the obesity market this year",
      "id": 132316373,
      "image": "https://imgproxy.divecdn.com/XpGY4jJ-UhBd7rm3HhwdAlVXa4GmJSVipcn88ZseUP0/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDkyNDczMjEzX2VHaVhSdTEuanBn.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.",
      "url": "https://finnhub.io/api/news?id=f3086c06d83cacc3193673dc327878c7d13d61343e637371455421df91c72968"
    }
  }
]